Annual report
3353.TEDINET S100QTLN
Period2022-03-01 → 2023-02-28
Filed2023-05-25
StandardJapan GAAP
ConsolidatedYes
Data checks22 of 22 passed
Key figures · 145
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥33.9bn | 2022-03-01 → 2023-02-28 | Cons. | Net sales |
| Revenue | ¥33.6bn | 2021-03-01 → 2022-02-28 | Cons. | Net sales |
| Revenue | ¥31.6bn | 2020-03-01 → 2021-02-28d | Cons. | Net sales (5-year summary) |
| Revenue | ¥32.0bn | 2019-03-01 → 2020-02-29d | Cons. | Net sales (5-year summary) |
| Revenue | ¥31.2bn | 2018-03-01 → 2019-02-28d | Cons. | Net sales (5-year summary) |
| Operating income | ¥935m | 2022-03-01 → 2023-02-28 | Cons. | Operating income |
| Operating income | ¥1.3bn | 2021-03-01 → 2022-02-28 | Cons. | Operating income |
| Ordinary income | ¥1.2bn | 2022-03-01 → 2023-02-28 | Cons. | Ordinary income |
| Ordinary income | ¥1.4bn | 2021-03-01 → 2022-02-28 | Cons. | Ordinary income |
| Ordinary income | ¥1.2bn | 2020-03-01 → 2021-02-28d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.2bn | 2019-03-01 → 2020-02-29d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.1bn | 2018-03-01 → 2019-02-28d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥1.3bn | 2022-03-01 → 2023-02-28 | Cons. | Income before income taxes |
| Profit before tax | ¥1.5bn | 2021-03-01 → 2022-02-28 | Cons. | Income before income taxes |
| Net income (owners) | ¥760m | 2022-03-01 → 2023-02-28 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥852m | 2021-03-01 → 2022-02-28 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥835m | 2020-03-01 → 2021-02-28d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥802m | 2019-03-01 → 2020-02-29d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥712m | 2018-03-01 → 2019-02-28d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥773m | 2022-03-01 → 2023-02-28 | Cons. | Profit loss |
| Net income | ¥869m | 2021-03-01 → 2022-02-28 | Cons. | Profit loss |
| Total assets | ¥27.5bn | at 2023-02-28 | Cons. | Assets |
| Total assets | ¥29.1bn | at 2022-02-28 | Cons. | Assets |
| Total assets | ¥28.6bn | at 2021-02-28d | Cons. | Total assets (5-year summary) |
| Total assets | ¥26.2bn | at 2020-02-29d | Cons. | Total assets (5-year summary) |
| Total assets | ¥26.2bn | at 2019-02-28d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥14.9bn | at 2023-02-28 | Cons. | Liabilities |
| Total liabilities | ¥17.2bn | at 2022-02-28 | Cons. | Liabilities |
| Net assets / equity | ¥12.6bn | at 2023-02-28 | Cons. | Net assets |
| Net assets / equity | ¥11.9bn | at 2022-02-28 | Cons. | Net assets |
| Net assets / equity | ¥10.5bn | at 2021-02-28d | Cons. | Net assets |
| Net assets / equity | ¥10.2bn | at 2020-02-29d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥9.6bn | at 2019-02-28d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥6.4bn | at 2023-02-28 | Cons. | Cash and deposits |
| Cash and deposits | ¥8.0bn | at 2022-02-28 | Cons. | Cash and deposits |
| Cash & equivalents | ¥6.3bn | at 2023-02-28 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.8bn | at 2022-02-28 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.8bn | at 2021-02-28d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.6bn | at 2020-02-29d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥5.2bn | at 2019-02-28d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥1.3bn | 2022-03-01 → 2023-02-28 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.1bn | 2021-03-01 → 2022-02-28 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.8bn | 2020-03-01 → 2021-02-28d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.8bn | 2019-03-01 → 2020-02-29d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥516m | 2018-03-01 → 2019-02-28d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥478m | 2022-03-01 → 2023-02-28 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥216m | 2021-03-01 → 2022-02-28 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.2bn | 2020-03-01 → 2021-02-28d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥375m | 2019-03-01 → 2020-02-29d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.3bn | 2018-03-01 → 2019-02-28d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥2.4bn | 2022-03-01 → 2023-02-28 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥65m | 2021-03-01 → 2022-02-28 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥591m | 2020-03-01 → 2021-02-28d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.1bn | 2019-03-01 → 2020-02-29d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥475m | 2018-03-01 → 2019-02-28d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥202.2 | 2022-03-01 → 2023-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥226.92 | 2021-03-01 → 2022-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥221.31 | 2020-03-01 → 2021-02-28d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥210.36 | 2019-03-01 → 2020-02-29d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥185.95 | 2018-03-01 → 2019-02-28d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥3,207.14 | at 2023-02-28 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,030.61 | at 2022-02-28 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,791.36 | at 2021-02-28d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,667.87 | at 2020-02-29d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,505.51 | at 2019-02-28d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 43.8% | at 2023-02-28 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.1% | at 2022-02-28 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.7% | at 2021-02-28d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.8% | at 2020-02-29d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.4% | at 2019-02-28d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 6.5% | 2022-03-01 → 2023-02-28 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.8% | 2021-03-01 → 2022-02-28 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.1% | 2020-03-01 → 2021-02-28d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.1% | 2019-03-01 → 2020-02-29d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.5% | 2018-03-01 → 2019-02-28d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,297 | at 2023-02-28 | Cons. | Number of employees |
| Employees | 1,325 | at 2022-02-28 | Cons. | Number of employees |
| Employees | 1,304 | at 2021-02-28d | Cons. | Number of employees |
| Employees | 1,187 | at 2020-02-29d | Cons. | Number of employees |
| Employees | 1,178 | at 2019-02-28d | Cons. | Number of employees |
| Revenue | ¥1.0bn | 2022-03-01 → 2023-02-28 | Standalone | Operating revenue1 |
| Revenue | ¥970m | 2021-03-01 → 2022-02-28 | Standalone | Operating revenue1 |
| Operating income | ¥491m | 2022-03-01 → 2023-02-28 | Standalone | Operating income |
| Operating income | ¥383m | 2021-03-01 → 2022-02-28 | Standalone | Operating income |
| Ordinary income | ¥592m | 2022-03-01 → 2023-02-28 | Standalone | Ordinary income |
| Ordinary income | ¥432m | 2021-03-01 → 2022-02-28 | Standalone | Ordinary income |
| Ordinary income | ¥319m | 2020-03-01 → 2021-02-28d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥492m | 2019-03-01 → 2020-02-29d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥697m | 2018-03-01 → 2019-02-28d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥613m | 2022-03-01 → 2023-02-28 | Standalone | Income before income taxes |
| Profit before tax | ¥461m | 2021-03-01 → 2022-02-28 | Standalone | Income before income taxes |
| Net income | ¥526m | 2022-03-01 → 2023-02-28 | Standalone | Profit loss |
| Net income | ¥397m | 2021-03-01 → 2022-02-28 | Standalone | Profit loss |
| Net income | ¥355m | 2020-03-01 → 2021-02-28d | Standalone | Net income loss (5-year summary) |
| Net income | ¥311m | 2019-03-01 → 2020-02-29d | Standalone | Net income loss (5-year summary) |
| Net income | ¥685m | 2018-03-01 → 2019-02-28d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥11.8bn | at 2023-02-28 | Standalone | Assets |
| Total assets | ¥12.5bn | at 2022-02-28 | Standalone | Assets |
| Total assets | ¥12.5bn | at 2021-02-28d | Standalone | Total assets (5-year summary) |
| Total assets | ¥12.4bn | at 2020-02-29d | Standalone | Total assets (5-year summary) |
| Total assets | ¥17.0bn | at 2019-02-28d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥3.2bn | at 2023-02-28 | Standalone | Liabilities |
| Total liabilities | ¥4.2bn | at 2022-02-28 | Standalone | Liabilities |
| Net assets / equity | ¥8.6bn | at 2023-02-28 | Standalone | Net assets |
| Net assets / equity | ¥8.3bn | at 2022-02-28 | Standalone | Net assets |
| Net assets / equity | ¥8.0bn | at 2021-02-28d | Standalone | Net assets |
| Net assets / equity | ¥8.2bn | at 2020-02-29d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥8.1bn | at 2019-02-28d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.8bn | at 2023-02-28 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.2bn | at 2022-02-28 | Standalone | Cash and deposits |
| EPS (basic) | ¥140.07 | 2022-03-01 → 2023-02-28 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥105.69 | 2021-03-01 → 2022-02-28 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥94.22 | 2020-03-01 → 2021-02-28d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥81.56 | 2019-03-01 → 2020-02-29d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥178.92 | 2018-03-01 → 2019-02-28d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥40 | 2022-03-01 → 2023-02-28 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2021-03-01 → 2022-02-28 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥80 | 2020-03-01 → 2021-02-28d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥85 | 2019-03-01 → 2020-02-29d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥80 | 2018-03-01 → 2019-02-28d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥2,293.7 | at 2023-02-28 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,196.84 | at 2022-02-28 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,131.98 | at 2021-02-28d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,143.92 | at 2020-02-29d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,112.94 | at 2019-02-28d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 73.2% | at 2023-02-28 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.3% | at 2022-02-28 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 64.3% | at 2021-02-28d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.9% | at 2020-02-29d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.3% | at 2019-02-28d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 6.2% | 2022-03-01 → 2023-02-28 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.9% | 2021-03-01 → 2022-02-28 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.4% | 2020-03-01 → 2021-02-28d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.8% | 2019-03-01 → 2020-02-29d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.7% | 2018-03-01 → 2019-02-28d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 4,070,000 | at 2023-02-28 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,070,000 | at 2022-02-28 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,035,000 | at 2021-02-28d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,035,000 | at 2020-02-29d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,035,000 | at 2019-02-28d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 25 | at 2023-02-28 | Standalone | Number of employees |
| Employees | 25 | at 2022-02-28 | Standalone | Number of employees |
| Employees | 25 | at 2021-02-28d | Standalone | Number of employees |
| Employees | 17 | at 2020-02-29d | Standalone | Number of employees |
| Employees | 481 | at 2019-02-28d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 83
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2022-03-01 → 2023-02-28 | ¥26m |
| Reconciling Itemsreconciling | depreciation | 2022-03-01 → 2023-02-28 | ¥34m |
| Reconciling Itemsreconciling | revenue | 2022-03-01 → 2023-02-28 | −¥1.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-03-01 → 2023-02-28 | −¥1.0bn |
| Reconciling Itemsreconciling | segment assets | at 2023-02-28 | ¥7.3bn |
| Reconciling Itemsreconciling | segment profit | 2022-03-01 → 2023-02-28 | −¥709m |
| Dispensing Pharmacyreportable segment | capex | 2022-03-01 → 2023-02-28 | ¥214m |
| Dispensing Pharmacyreportable segment | depreciation | 2022-03-01 → 2023-02-28 | ¥160m |
| Dispensing Pharmacyreportable segment | employees | at 2023-02-28 | 462 pure |
| Dispensing Pharmacyreportable segment | revenue | 2022-03-01 → 2023-02-28 | ¥23.1bn |
| Dispensing Pharmacyreportable segment | revenue external | 2022-03-01 → 2023-02-28 | ¥23.1bn |
| Dispensing Pharmacyreportable segment | segment assets | at 2023-02-28 | ¥7.8bn |
| Dispensing Pharmacyreportable segment | segment profit | 2022-03-01 → 2023-02-28 | ¥1.5bn |
| Health Carereportable segment | capex | 2022-03-01 → 2023-02-28 | ¥67m |
| Health Carereportable segment | depreciation | 2022-03-01 → 2023-02-28 | ¥389m |
| Health Carereportable segment | employees | at 2023-02-28 | 776 pure |
| Health Carereportable segment | revenue | 2022-03-01 → 2023-02-28 | ¥7.7bn |
| Health Carereportable segment | revenue external | 2022-03-01 → 2023-02-28 | ¥7.7bn |
| Health Carereportable segment | revenue intersegment | 2022-03-01 → 2023-02-28 | ¥600,000 |
| Health Carereportable segment | segment assets | at 2023-02-28 | ¥9.5bn |
| Health Carereportable segment | segment profit | 2022-03-01 → 2023-02-28 | −¥29m |
| Medical Products Wholesalereportable segment | depreciation | 2022-03-01 → 2023-02-28 | ¥12m |
| Medical Products Wholesalereportable segment | employees | at 2023-02-28 | 33 pure |
| Medical Products Wholesalereportable segment | revenue | 2022-03-01 → 2023-02-28 | ¥3.9bn |
| Medical Products Wholesalereportable segment | revenue external | 2022-03-01 → 2023-02-28 | ¥2.9bn |
| Medical Products Wholesalereportable segment | revenue intersegment | 2022-03-01 → 2023-02-28 | ¥998m |
| Medical Products Wholesalereportable segment | segment assets | at 2023-02-28 | ¥1.3bn |
| Medical Products Wholesalereportable segment | segment profit | 2022-03-01 → 2023-02-28 | ¥57m |
| Real Estatereportable segment | capex | 2022-03-01 → 2023-02-28 | ¥6m |
| Real Estatereportable segment | depreciation | 2022-03-01 → 2023-02-28 | ¥37m |
| Real Estatereportable segment | employees | at 2023-02-28 | 1 pure |
| Real Estatereportable segment | revenue | 2022-03-01 → 2023-02-28 | ¥189m |
| Real Estatereportable segment | revenue external | 2022-03-01 → 2023-02-28 | ¥187m |
| Real Estatereportable segment | revenue intersegment | 2022-03-01 → 2023-02-28 | ¥2m |
| Real Estatereportable segment | segment assets | at 2023-02-28 | ¥1.6bn |
| Real Estatereportable segment | segment profit | 2022-03-01 → 2023-02-28 | ¥125m |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-03-01 → 2023-02-28 | ¥286m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-03-01 → 2023-02-28 | ¥598m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-03-01 → 2023-02-28 | ¥34.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-03-01 → 2023-02-28 | ¥33.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-03-01 → 2023-02-28 | ¥1.0bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-02-28 | ¥20.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-03-01 → 2023-02-28 | ¥1.6bn |
| Reconciling Itemsreconciling | capex | 2021-03-01 → 2022-02-28 | ¥153m |
| Reconciling Itemsreconciling | depreciation | 2021-03-01 → 2022-02-28 | ¥40m |
| Reconciling Itemsreconciling | revenue | 2021-03-01 → 2022-02-28 | −¥1.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-03-01 → 2022-02-28 | −¥1.1bn |
| Reconciling Itemsreconciling | segment assets | at 2022-02-28 | ¥8.0bn |
| Reconciling Itemsreconciling | segment profit | 2021-03-01 → 2022-02-28 | −¥736m |
| Dispensing Pharmacyreportable segment | capex | 2021-03-01 → 2022-02-28 | ¥176m |
| Dispensing Pharmacyreportable segment | depreciation | 2021-03-01 → 2022-02-28 | ¥144m |
| Dispensing Pharmacyreportable segment | revenue | 2021-03-01 → 2022-02-28 | ¥22.7bn |
| Dispensing Pharmacyreportable segment | revenue external | 2021-03-01 → 2022-02-28 | ¥22.7bn |
| Dispensing Pharmacyreportable segment | segment assets | at 2022-02-28 | ¥7.6bn |
| Dispensing Pharmacyreportable segment | segment profit | 2021-03-01 → 2022-02-28 | ¥1.5bn |
| Health Carereportable segment | capex | 2021-03-01 → 2022-02-28 | ¥33m |
| Health Carereportable segment | depreciation | 2021-03-01 → 2022-02-28 | ¥397m |
| Health Carereportable segment | revenue | 2021-03-01 → 2022-02-28 | ¥7.8bn |
| Health Carereportable segment | revenue external | 2021-03-01 → 2022-02-28 | ¥7.8bn |
| Health Carereportable segment | revenue intersegment | 2021-03-01 → 2022-02-28 | ¥600,000 |
| Health Carereportable segment | segment assets | at 2022-02-28 | ¥10.5bn |
| Health Carereportable segment | segment profit | 2021-03-01 → 2022-02-28 | ¥219m |
| Medical Products Wholesalereportable segment | capex | 2021-03-01 → 2022-02-28 | ¥8m |
| Medical Products Wholesalereportable segment | depreciation | 2021-03-01 → 2022-02-28 | ¥8m |
| Medical Products Wholesalereportable segment | revenue | 2021-03-01 → 2022-02-28 | ¥3.9bn |
| Medical Products Wholesalereportable segment | revenue external | 2021-03-01 → 2022-02-28 | ¥2.8bn |
| Medical Products Wholesalereportable segment | revenue intersegment | 2021-03-01 → 2022-02-28 | ¥1.1bn |
| Medical Products Wholesalereportable segment | segment assets | at 2022-02-28 | ¥1.3bn |
| Medical Products Wholesalereportable segment | segment profit | 2021-03-01 → 2022-02-28 | ¥114m |
| Real Estatereportable segment | depreciation | 2021-03-01 → 2022-02-28 | ¥40m |
| Real Estatereportable segment | revenue | 2021-03-01 → 2022-02-28 | ¥233m |
| Real Estatereportable segment | revenue external | 2021-03-01 → 2022-02-28 | ¥232m |
| Real Estatereportable segment | revenue intersegment | 2021-03-01 → 2022-02-28 | ¥2m |
| Real Estatereportable segment | segment assets | at 2022-02-28 | ¥1.7bn |
| Real Estatereportable segment | segment profit | 2021-03-01 → 2022-02-28 | ¥130m |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-03-01 → 2022-02-28 | ¥216m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-03-01 → 2022-02-28 | ¥588m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-03-01 → 2022-02-28 | ¥34.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-03-01 → 2022-02-28 | ¥33.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-03-01 → 2022-02-28 | ¥1.1bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-02-28 | ¥21.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-03-01 → 2022-02-28 | ¥2.0bn |
| Real Estatereportable segment | employees | at 2023-02-28 | 1 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,435
| Item | Context | Value | Unit |
|---|---|---|---|
| Average number of temporary workers | Prior1YearInstant_NonConsolidatedMember | 1 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 1 | |
| Total shareholder return | Prior4YearInstant_NonConsolidatedMember | 0.787 | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 0.759 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 0.539 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 0.467 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 0.480 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | 0.929 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 0.895 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 1.132 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 1.170 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 1.270 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E03443-000DispensingPharmacyReportableSegmentsMember | 462 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E03443-000DispensingPharmacyReportableSegmentsMember | 132 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E03443-000HealthCareReportableSegmentsMember | 776 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E03443-000HealthCareReportableSegmentsMember | 255 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E03443-000MedicalProductsWholesaleReportableSegmentsMember | 33 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E03443-000MedicalProductsWholesaleReportableSegmentsMember | 31 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E03443-000RealEstateReportableSegmentsMember | 1 | |
| Number of employees | CurrentYearInstant_CorporateSharedMember | 25 | |
| Average number of temporary workers | CurrentYearInstant_CorporateSharedMember | 3 | |
| Number of employees | CurrentYearInstant | 1297 | |
| Average number of temporary workers | CurrentYearInstant | 421 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 25 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 40.5 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 12.4 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 5617000 | JPY |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 1 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E03443-000RealEstateReportableSegmentsMember | 1 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 24 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 1 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 25 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 1 | |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 555000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E03443-000DispensingPharmacyReportableSegmentsMember | 455000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E03443-000HealthCareReportableSegmentsMember | 67000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E03443-000MedicalProductsWholesaleReportableSegmentsMember | 0 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E03443-000RealEstateReportableSegmentsMember | 5000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_CorporateSharedMember | 26000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 4070000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 4070000 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 4070000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 4070000 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 6 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 10 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 26 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 8 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | － |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 22 of 22 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |